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WHAT THE PUBLIC WANTS 
(and maybe expects) 
•  All Drugs work All the Time for All People 
•  All Drugs are Safe All the Time for All 
People 
•  All Drugs are Cheap All the Time for All 
People 
The Reality is that none of the above three 
are true. 
IS THE UNIVERSAL BLACK BOX 
WARNING THE SOLUTION???? 
This drug poses both known and unknown 
risks.  Some of these risks may be severe 
and even result in death.  The known risks 
are described in this product label.  The 
unknown risks are still unknown. 
© Alan Goldhammer 
Key Facts 
Research and Development 
• Time to develop a drug = 10 – 15 years1 
R&D Spending 
 Development Costs 
• Cost to develop a drug 
 2006 = $1,318 million2 
 2001 = $802 million3 
 1987 = $318 million3 
 1975 = $138 million3 
• Cost to develop a biologic 
 2006 = $1.2 billion4 
Percentage of Sales That 
Went to R&D in 2007 
Domestic R&D as a percentage of 
domestic sales = 18.7%5 
Total R&D as a percentage of 
total sales = 16.4%5 
Total National Institutes 
of Health Funding11 
(Part of this budget is allotted for developing 
drugs.) 
•   2008 = $28.9 billion 
•   2007 = $28.6 billion 
•   2006 = $28.5 billion 
Year PhRMA members6 Total industry 
200
7 $44.5 billion (est.) $58.8 billion (est.)
7 
200
6 $43.4 billion $56.1 billion
8 
200
5 $39.9 billion $51.8 billion
9 
200
4 $37.0 billion $47.6 billion
10 
200
0 $26.0 billion not available 
199
0 $8.4 billion not available 
198
0 $2.0 billion not available 
Sources: See Key Facts Sources slide. 
Figure 2  The R&D Process: 
Long, Complex, and Costly 
Drug Development in an 
Interactive Process   
•  FDA is Consulted from the Early Stages of 
Development Regarding Clinical Trial 
Protocols 
•  FDA Receives and Reviews all the Data 
•  FDA Ultimately Approves the Drug Label 
from which all Communication about the 
Drug Flows 
TWO CRITICAL ISSUES IN 
DRUG DEVELOPMENT 
•  Cost – Current Estimate to Bring a New 
Molecule to Market is Approximately $1.3 
Billion 
•  Time – Because of Scientific 
Uncertainties and Regulatory Compliance 
it takes 10-15 years from Discovery to 
Licensure 
Despite this effort, we don’t fully 
know the drug’s safety profile (or 
for that matter the full efficacy) 
HOW DO WE MEASURE 
SUCCESS? 
Drug Approval = f(benefit/risk) 
•  Benefit – Expected Positive Clinical 
Outcome 
•  Risk = p(harm) x severity(harm)  
•  The overall assessment of risk is 
dependent on the benefit (and the 
severity of the medical indication being 
treated) 
THE ROADMAP TO SUCCESS 
1)  Identify the Therapeutic Target 
(enzyme/receptor) 
2)  Translate in vitro Observation to in vivo 
Activity 
3)  Identify Safety Issues (pre-clinical & 
clinical) 
4)  Demonstrate Efficacy 
•  Keys to Steps 1-4 is Deciding when to Pull the 
Plug (e.g., stop development) 
5)  Continue to Study Safety (post-market) 
Sources of Risk from Drug Products 













•  Unexpected side effects 
•  Unstudied uses 
•  Unstudied populations 
HOW TO COMMUNICATE 
BENEFIT & RISK 
•  Drug Label (Package Insert) 
•  Patient Package Insert 
•  Medication Guide 
•  Consumer Medical Information 
•  DTC 
•  Print, Broadcast, Internet 
•  Other Sources (FDA; Internet) 
TWO SMALL (or VERY BIG) 
STEPS 
Let’s all work to insure that every 
patient has realistic expectations 
about the medicine they are 
prescribed. 
Make sure that the patient has the 
right drug at the right time for his/
her medical condition 
